Claims for Patent: 10,561,659

Summary for Patent: 10,561,659

Title:	Treatment of hair loss disorders with deuterated JAK inhibitors
Abstract:	Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an amount in the range of about 4 mg to about 50 mg of Compound (I), or a pharmaceutically acceptable salt thereof. This invention also provides compositions comprising Compound (I) and the use of such compositions in the described methods.
Inventor(s):	Wagner Amanda T., Cassella James V., Graham Philip B., Braman Virginia, Uttamsingh Vinita, Von Hehn Jana, Hamilton Colleen E.
Assignee:	Concert Pharmaceuticals, Inc.
Application Number:	US16098338
Patent Claims:	2. The method of claim 1 , wherein the hair loss disorder is alopecia areata.3. The method of any one of claim 1 , wherein the compound is administered orally.4. The method of claim 1 , wherein the compound is administered in a pharmaceutical formulation which is a tablet.5. The method of claim 1 , wherein the compound is administered once a day.6. The method of claim 1 , wherein the compound is administered twice a day.7. The method of claim 1 , wherein in Compound (I) claim 1 , any atom not designated as deuterium is present at its natural isotopic abundance.10. The method of claim 9 , wherein Compound (I) is administered as 10.5 mg of the phosphate salt twice per day.12. The method of claim 11 , wherein Compound (I) is administered as 15.8 mg of the phosphate salt twice per day.13. The method of claim 1 , wherein each position in Compound (I) designated specifically as deuterium has at least 97% incorporation of deuterium.14. The method of claim 1 , wherein the step of administering comprises administering to the subject 8 mg twice per day or 12 mg twice per day of Compound (I).15. The method of claim 9 , wherein the hair loss disorder is alopecia areata.16. The method of claim 9 , wherein the compound is administered orally.17. The method of claim 9 , wherein each position in Compound (I) designated specifically as deuterium has at least 97% incorporation of deuterium.18. The method of claim 11 , wherein the hair loss disorder is alopecia areata.19. The method of claim 11 , wherein compound is administered orally.20. The method of claim 11 , wherein each position in Compound (I) designated specifically as deuterium has at least 97% incorporation of deuterium.21. The method of claim 14 , wherein the subject is a human.